Welcome to our dedicated page for Claritev news (Ticker: CTEV), a resource for investors and traders seeking the latest updates and insights on Claritev stock.
Claritev Corporation (NYSE: CTEV) is a healthcare technology, data and insights company that regularly issues news on its role in improving healthcare affordability, transparency and quality. As a health information services and healthcare technology provider, Claritev uses AI-driven analytics and decades of claims experience to support payors, employers, providers, patients and third parties across the healthcare ecosystem. Its news flow reflects both operating performance and strategic initiatives tied to this mission.
On this page, readers can follow Claritev news related to quarterly financial results, investor presentations and participation in major healthcare and finance conferences. The company frequently announces earnings for periods such as its third quarter, along with updates on revenues, net income or loss, Adjusted EBITDA and other financial metrics. These releases often include commentary on business momentum, guidance updates and the scale of claim charges processed and potential medical cost savings identified.
Claritev also publishes news about client relationships and contracts, including renewals with its largest clients and information about multi-year agreements that cover a significant share of its revenues. In addition, the company highlights strategic partnerships and international initiatives, such as agreements to deliver AI-powered revenue cycle management platforms in the Middle East and North Africa and investments in healthcare payment-acceleration providers that connect its U.S. presence with activity in the MENA region.
Other Claritev announcements include brand and sponsorship activities, such as golf sponsorships with professional players that the company positions as ambassadors for its values. For investors, analysts and observers of the healthcare technology sector, this news page provides a centralized view of Claritev’s public disclosures, from financial updates and capital markets transactions to technology collaborations and market expansion efforts.
Claritev (NYSE: CTEV) has announced two key appointments to strengthen its leadership team as part of its business transformation strategy. Dr. Jigar S. Patel will join as Chief Medical Officer effective April 14, 2025, bringing over 18 years of experience from Cerner/Oracle. He will provide medical guidance on strategic development and product innovation of Claritev's healthcare technology solutions.
Dr. Fernando Schwartz has been appointed as Chief Artificial Intelligence Officer, effective February 17, 2025. With 15 years of leadership in data science and machine learning, Schwartz previously served as VP of AI at ADP and led global data science strategy at Merck's Human Health Division. He will lead the company's AI and analytics strategy under Chief Digital Officer Michael Kim.
Claritev (NYSE: CTEV) announced that its data solution Ceres® has won the 'Data Solution of the Year for Insurance' award in the 6th annual Data Breakthrough Awards' Industry Applications Category. Ceres is designed to help supplemental carriers and benefits brokers provide unbiased benefit recommendations.
The platform leverages AI-powered insights and de-identified claims data from over a million members to transform supplemental plan design from an intuition-based process into a data-driven approach. The solution enables modeling of different census scenarios to determine which benefits provide the highest value through predicted utilization and payout amounts, benchmarked against similar employer groups.
According to Travis Dalton, Chairman, CEO and President of Claritev, Ceres exemplifies their philosophy that data and technology should empower rather than replace people. The platform aims to shift focus from lowest-cost offerings to high-value, population-specific plans.
Claritev (NYSE: CTEV) has scheduled its first quarter 2025 earnings conference call for Thursday, May 8, 2025, at 8:00 am Eastern Time. The company will release its Q1 2025 financial results the same day.
Participants can pre-register for the call through a provided link, after which they will receive a calendar invitation with access details and a unique PIN. A live webcast will be accessible through the company's Investor Relations website at investors.claritev.com/events-and-presentations, with participants advised to join ten minutes before the start time.
The earnings press release and supplemental slide deck will be available on the company website. For those unable to attend live, a replay will be available approximately two hours after the call through the archived webcast. Operator assistance is available at (404) 975-4839 or (833) 470-1428 with access code 685315.
Claritev (NYSE: CTEV), a healthcare technology company, has announced a sponsorship agreement with professional golfer Neal Shipley. As part of the deal, Shipley will display the Claritev logo on his shirt collar during competitions.
Shipley, 24, turned professional in summer 2024 following a notable amateur career where he made history as the low amateur at both the 2024 Masters Tournament and U.S. Open - becoming the ninth golfer in PGA TOUR history to achieve this distinction in the same year. He currently competes on the PGA TOUR Americas and has received sponsor exemptions for multiple PGA TOUR events.
The rising golf star was recently featured in the third season of Netflix's docuseries Full Swing, which captured his journey to the 2024 Masters and his experience playing alongside Tiger Woods in the final round.
ClearNote Health has announced a new agreement with Claritev (NYSE: CTEV) to make its Avantect® Pancreatic Cancer Test available through Claritev's national PHCS and MultiPlan Networks. The test is a DNA-based blood screening that combines epigenomic and genomic signals with machine learning to detect early pancreatic cancer indicators.
The Avantect test specifically targets high-risk patients, including:
- Type 2 diabetes patients aged 50 and older
- Individuals with relevant family history
- People with genetic predisposition
The test utilizes 5-hydroxymethylcytosine (5hmC) profiling in cell-free DNA and AI algorithms to detect tumor development earlier than conventional methods. This is particularly significant as pancreatic cancer often has only a 3% five-year survival rate when diagnosed at advanced stages.